Showing results (171-180 of 192) with videos related to
Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib StudySamuel A Jacobs, James J Lee, Thomas J George, et al.Biorxiv : the Preprint Server for Biology|February 26, 2024
Mitigation of Fetal Irradiation Injury from Mid-Gestation Total Body Radiation with Mitochondrial-Targeted GS-Nitroxide JP4-039Yijen L Wu, Anthony G Christodoulou, Jan H Beumer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)Michael J Morris, Glenn Heller, David W Hillman, et al.British Journal of Clinical Pharmacology|July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunctionNaoko Takebe, Jan H Beumer, Shivaani Kummar, et al.Clinical Journal of the American Society of Nephrology : CJASN|June 7, 2024
Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-NephrologyAbhijat Kitchlu, Verônica T Costa E Silva, Shuchi Anand, et al.Cancer Prevention Research (Philadelphia, Pa.)|April 26, 2018
Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical NeviShawn Tahata, Shivendra V Singh, Yan Lin, et al.Radiation Research|July 29, 2024
Mitigation of Fetal Radiation Injury from Mid-Gestation Total-body Irradiation by Maternal Administration of Mitochondrial-Targeted GS-Nitroxide JP4-039Yijen L Wu, Anthony G Christodoulou, Jan H Beumer, et al.Cancer Chemotherapy and Pharmacology|December 22, 2025
A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumorsAlice P Chen, Shivaani Kummar, Larry Rubinstein, et al.Cancer Chemotherapy and Pharmacology|April 22, 2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumorsGeraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, et al.The Lancet. Oncology|December 4, 2013
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trialSung Won Choi, Thomas Braun, Lawrence Chang, et al.Pageof 20